Kuzucu İhsan, Çandar Tuba, Baklacı Deniz, Güler İsmail, Kum Rauf Oğuzhan, Arslan Hande, Özcan Müge
Department of Otorhinolaryngology, Ankara Numune Training and Research Hospital, Ankara, Turkey.
Department of Biochemistry, Ufuk University, Ankara, Turkey.
Clin Exp Otorhinolaryngol. 2020 Feb;13(1):36-40. doi: 10.21053/ceo.2019.00283. Epub 2019 Jul 26.
Calprotectin, a protein released by neutrophils, has been used in many studies as a biomarker showing the presence of inflammation. In this study, it was aimed to investigate the relationship between serum calprotectin level and response to the treatment of idiopathic sudden sensorineural hearing loss (ISSHL).
The present study is a prospective, cross-sectional historical cohort study. The study group consisted of 44 patients with ISSHL, and the control group consisted of 41 healthy volunteers without ear pathology. At the same time, patients in the study group were divided into three groups according to the response to ISSHL treatment (recovered, partially recovered, unrecovered). The relationship between the groups was statistically evaluated in terms of serum calprotectin levels.
The mean serum calprotectin value was 75.67±19.48 ng/mL in the study group and 50.24±29.14 ng/mL in the control group (P=0.001). Serum calprotectin value according to the severity of hearing loss in the mild, moderate and severe was 66.20±8.82, 70.35±16.77, and 91.23±19.73 ng/mL, respectively. Serum calprotectin value in the severe group was significantly higher compared to the moderate and mild groups (P=0.004, P=0.001, respectively). Serum calprotectin value according to the treatment response in the recovered, partially recovered and unrecovered groups was 63.36±11.54, 80.17±12.06, and 85.33±22.33 ng/mL, respectively. Serum calprotectin value in the recovered group was significantly lower compared to the partially recovered and unrecovered groups (P=0.002, P=0.001, respectively).
Serum calprotectin value informs the clinician about both the severity of hearing loss and the response to treatment. Hence, serum calprotectin can be used as an important biomarker in ISSHL patients for the determination of the prognosis of disease.
钙卫蛋白是一种由中性粒细胞释放的蛋白质，在许多研究中被用作显示炎症存在的生物标志物。本研究旨在探讨血清钙卫蛋白水平与特发性突发性感音神经性听力损失（ISSHL）治疗反应之间的关系。
本研究是一项前瞻性、横断面历史性队列研究。研究组由44例ISSHL患者组成，对照组由41名无耳部病变的健康志愿者组成。同时，研究组患者根据ISSHL治疗反应分为三组（恢复、部分恢复、未恢复）。对各组之间血清钙卫蛋白水平的关系进行统计学评估。
研究组血清钙卫蛋白平均值为75.67±19.48 ng/mL，对照组为50.24±29.14 ng/mL（P = 0.001）。轻度、中度和重度听力损失患者的血清钙卫蛋白值分别为66.20±8.82、70.35±16.77和91.23±19.73 ng/mL。重度组血清钙卫蛋白值明显高于中度和轻度组（分别为P = 0.004，P = 0.001）。恢复、部分恢复和未恢复组的血清钙卫蛋白值分别为63.36±11.54、80.17±12.06和85.33±22.33 ng/mL。恢复组血清钙卫蛋白值明显低于部分恢复和未恢复组（分别为P = 0.002，P = 0.001）。
血清钙卫蛋白值可为临床医生提供听力损失严重程度和治疗反应的信息。因此，血清钙卫蛋白可作为ISSHL患者疾病预后判定的重要生物标志物。
